James Mulloy C PhD


James Mulloy C PhD
Asst ProfessorCollege of Medicine--UCjames.Mulloy@cchmc.org
S7.603/ML 7013 3333 Burnet Ave Cincinnati OH 45229
Phone:(513) 636-1844Fax: (513) 636-3768
  • Leukemia Research

General Research Interest

Leukemia, hematopoiesis, transcription factor activity, epigenetics, xenograft leukemia model, survival signaling in leukemia

Research Description

Research in the Mulloy Laboratory focuses on using human hematopoietic stem/progenitor cells (HSPC) to model leukemia. The prevailing theory is that acute myeloid leukemia is a stem cell disease. We believe the technology and expertise are now available that permit us to use primary human HSPC to dissect the stepwise progression of human AML. As a proof of principal, we have expressed the AML1-ETO fusion protein in human CD34+ cells by retroviral transduction and characterized the genetic and functional alterations that occur due to expression of this oncogene These studies have recently been extended to two additional oncogenes, CBFb-MYH11 and MLL-AF9.

Transinstitutional Work

The Mulloy lab is currently collaborating with the laboratory of Dr. Guido Marcucci, using constitutively active mutants of the c-kit protein in cooperative leukemia initiation studies with the AML1-ETO and CBFb-MYH11 oncoproteins.

Current Publications

  • Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link K, Nassar N, Mulloy James CCBL restricts myeloid proliferation of human AML1-ETO preleukemia cells.Exp Hematol 42 S36 8/1/2014
  • Wunderlich M, Brooks RA, Panchal R, Rhyasen GW, Danet-Desnoyers G, Mulloy JCOKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.Blood 123 e134-44 6/12/2014
  • Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang JCombined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.J Clin Invest 124 2762-73 6/2/2014
  • Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DTAn MDS xenograft model utilizing a patient-derived cell line.Leukemia 28 1142-5 5/1/2014
  • Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G, Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse WDownregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.Blood 123 1729-38 3/13/2014
  • Grimes HL, Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein BTherapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.J Clin Invest 124 222-36 1/2/2014
  • Mulloy JCA new inducible model for t(8;21) AML.EMBO Mol Med 5 1795-7 12/1/2013
  • Goyama S, Mulloy JCNF-κB: a coordinator for epigenetic regulation by MLL.Cancer Cell 24 401-2 10/14/2013
  • Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Mulloy JC, Bhatia R, Marcucci G, Perrotti DPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest 123 4144-57 10/1/2013
  • Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JCTranscription factor RUNX1 promotes survival of acute myeloid leukemia cells.J Clin Invest 123 3876-88 9/3/2013
  • Araten DJ, Krejci O, Ditata K, Wunderlich M, Sanders KJ, Zamechek L, Mulloy JCThe rate of spontaneous mutations in human myeloid cells.Mutat Res 749 49-57 9/1/2013
  • Liu PP, Rowley JD, Xu M, He C, Chen J, Huang H, Jiang X, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin PTET1 plays an essential oncogenic role in MLL-rearranged leukemia.Proc Natl Acad Sci U S A 110 11994-9 7/16/2013
  • Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, He C, Gurbuxani S, Kunjamma RB, Huang H, Jiang X, Arnovitz S, Xu M, Hong GM, Elkahloun AG, Neilly MB, Wunderlich M, Larson RA, Le Beau MM, Mulloy JC, Liu PP, Rowley JD, Chen JmiR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.Proc Natl Acad Sci U S A 110 11511-6 7/9/2013
  • Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT, Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller JTargeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.Cancer Cell 24 90-104 7/8/2013
  • Li G, Wunderlich M, Mulloy JC, Merino EJ, Bell-Horwath TR, Vadukoot AK, Thowfeik FSNovel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia.Bioorg Med Chem Lett 23 2951-4 5/15/2013
  • Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JCAML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.Blood 121 e90-7 3/21/2013
  • Goyama S, Mulloy JCMaking healthy stem cells: the new role of TPO.Cell Stem Cell 12 8-9 1/3/2013
  • Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen JMiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.Proc Natl Acad Sci U S A 109 19397-402 11/20/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu